Icon times
Sun Pharmaceutical Industries Stock Fundamental Analysis - Financial Results & Equity Research | Invest Yadnya Stock-o-Meter

Sun Pharmaceutical Industries

CompanyOver

 / 
error iconThis ratio is already added in the table

About

Founded in 1982 by Mr Dilip Sanghvi in Gujarat Sun Pharma is one of the largest Indian pharmaceutical companies, with a leading position in the high growth chronic segments. The company’s product mix comprises of both formulations & bulk drugs. The company has undertaken recent acquisitions in order to pivot into global specialty business. Its key therapeutic area in domestic formulation are cardiology, neurology and gastroenterology, anti-infectives, anti-diabetic. Company derives 30% of revenue from US formulations,30% of revenue from Branded Business in India,17% of revenue from Emerging Markets,14% of revenue from Rest of the World & 6% of revenue from API.

Highlights

Performing rate for the company

Price Chart (Only Standalone)

Track the companies of Group.

Relaince Group

Sector: Refineries

Market Price

2,529.50

Market Cap(₹Cr.)

2,529.50

-90.00

Quarterly Results ( Figures in Rs. Crores.)

No Data is available.

Profit & Loss ( Figures in Rs. Crores.)

No Data is available.

Balance Sheet ( Figures in Rs. Crores.)

No Data is available.

Cash Flows ( Figures in Rs. Crores.)

No Data is available.

Historical Growths

Compounded Sales Growth
Compounded Profit Growth
Compounded Expense Growth
Stock Price CAGR
Sales Growth Profit Growth Expense Growth Stock Price CAGR

Ratios ()

No Data is available.

Major Shareholders

No Data is available.

Shareholders more than 1%

No Data is available.

Fund houses invested in the stock (Figures in % Equity Capital )

No Data is available.

Corporate Action

No Data is available.
No Data is available.
No Data is available.
No Data is available.

Documents

Presentation & Earning Calls

Annual Reports

Credit Rating

No document is available
No document is available
No document is available
No document is available.

Overview

Sun Pharmaceutical Industries established in 1983 with five psychiatry products and a two person marketing team. Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. It provide high-quality, affordable medicines trusted by healthcare professionals and patients in many countries worldwide. Sun Pharma is also India’s largest and pharmaceutical company. Its global presence is supported by several manufacturing facilities across few continents. In the US market which contributes a significant share of its revenues, the company is the leader in the generic dermatology segment. It has strong capabilities in developing generic and complex products with a robust pipeline of many ANDAs, including high value First-to-File (FTF) opportunities. It has an established presence in Europe and key high-growth Emerging Markets (EM) like Russia, Romania, South Africa, Brazil and Malaysia. The company’s primary focus is to in-license generic and differentiated generic products that are close to commercialization or in advanced stage of development for North America, Western Europe and Japan markets.

The company is market leader in India and it is interested in partnerships for late stage and/or marketed opportunities complementary to its commercial footprint or expansion within its core areas of focus in India. These include CNS disorders, Cardiology, Diabetes and Metabolic disorders, Gastroenterology, Ophthalmology, Oncology, Pain, Rheumatology, Allergy, Asthma and Inflammation and Gynecology. Its focus is for NCEs, NBEs, NDDS based differentiated products, Biosimilars, Proprietary Technology Barrier Products which provide it the first mover advantage in India. The company’s leadership position in India allows it to offer significant value to innovator companies who want to partner with a dynamic and leading company, capable of successfully marketing its assets and willing to give the right priority to in-licensed or partnered projects.

Business area of the company

The company is among the largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in many countries across the world, at affordable prices.

Products

Formulations
Active Pharmaceutical Ingredients - Crams
OTC
Awards
2005:  Dilip Shanghvi is named Entrepreneur of the Year (Healthcare and Life Science) Ernst & Young.
2007: Dilip Shanghvi is recognised as First Generation Entrepreneur of the Year CNBC-TV18.
2007: Dilip Shanghvi wins Pharmaceutical Companies IMC Juran Quality Medal IMC Ramkrishna Bajaj National Quality Award Trust.
2008: Sun Pharma wins Outstanding Exporter of the Year: Pharmaceuticals, Healthcare and Lifesciences Award CNBC TV 18:The International Trade Awards.
2008: Sun Pharma receives Business Leadership Award NDTV Profit.
2008: Dilip Shanghvi is named CEO of the Year Business Standard.
2008: Dilip Shanghvi is honoured with Entrepreneur of the Year Award The Economic Times.
2009: Sudhir V. Valia is named Best CFO in Pharma and Healthcare CNBC-TV18 CFO Awards.
2009: Sun Pharma receives Rolta Corporate Award: Pharmaceuticals Dun & Bradstreet.
2010: Dilip Shanghvi receives Entrepreneur of the Year Award Ernst & Young.
2010: Sun Pharma receives Business Leadership of the Year Award NDTV PROFIT.
2011: Dilip Shanghvi is recognised as World Entrepreneur of the Year Ernst & Young.
2011: Dilip Shanghvi is honoured with Businessman of the Year Award Business India.
2011: Dilip Shanghvi is named Indian of the Year (Business) CNN IBN.
2011: Sudhir V. Valia is named Best CFO in Pharma and Healthcare CNBC-TV18 CFO Awards.
2011: Sun Pharma is hailed as the Pharmaceutical Company of the Year Frost & Sullivan India Healthcare Excellence Awards.
2012: Sun Pharma is named Most Outstanding Company of the Year CNBC-TV18 India Business Leader Awards.
2012: Sun Pharma is listed among The World’s 100 Most Innovative Companies Forbes.
2012: Sun Pharma is listed in Asia's Fab 50 Companies Forbes.
2012: Sun Pharma wins Business Leadership of the Year - Pharmaceutical Award NDTV Profit.
2013: Uday Baldota receives Best CFO in Pharma and Healthcare Award CNBC TV-18 CFO Awards.
2013: Sun Pharma is named Company of the Year The Economic Times.
2013: Sun Pharma is named Company of the Year Business Standard.
2013: Sun Pharma is listed among Asia's Fab 50 Companies Forbes.
2014: Dilip Shanghvi receives Entrepreneur of the Year Award Forbes Magazine.
2014: Sun Pharma receives Cardiovascular Pharmaceutical Company of the Year Award Frost & Sullivan India Healthcare Excellence Awards.
2014: Dilip Shanghvi receives Business Leader of the Year Award The Economic Times.
2014: Sun Pharma is listed among The World’s 100 Most Innovative Companies Forbes.
2014: Dilip Shanghvi receives JRD TATA Corporate Leadership Award All India Management Association.
2015: Dilip Shanghvi receives Business Leader of the Year Award NDTV.
2015: Sun Pharma receives Excellence in CSR Award “India Pharma Awards - 2015” instituted by UBM-India.
2015: Sun Pharma receives India Pharma Research & Development Award 2015 Ministry of Chemicals & Fertilizers, Government of India.
2016: Sun Pharmaceutical Industries Inc. receives DIANA (Distribution Industry Award for Notable Achievements) Award Healthcare Distribution Alliance, USA.
2016: Dilip Shanghvi receives Padma Shri Award Government of India.
2016: Sun Pharma receives Community Care Award ASSOCHAM (Associated Chambers of Commerce).
2017: Dilip Shanghvi receives Entrepreneur of the Year Award All India Management Association (AIMA).
2018: Dilip Shanghvi receives Lifetime Outstanding Achievement Award Indore Management Association (IMA).
2018: Sun Pharma receives Outstanding Contribution in CSR Federation of Gujarat Industries.
2018: Sun Pharma receives Best CSR Practices The Economic Times (ET).
Milestones
Establishment & Growth
1983: The Company established with five psychiatry products and a two person marketing team
1994: The Company lunches IPO
1996: The Company expands sales network across 24 countries.
2007: The Company demerges Sun Pharma Advanced Research Company (SPARC) into a separate entity becoming the first pure research company to be listed on India Stock Exchanges.
2013: Ranbaxy acquisition catapults Sun Pharma to world’s 5th largest specialty generic pharmaceutical company.
Acquisitions & Alliances
1996: The Company acquires API plant from Knoll Pharma at Ahmednagar, Maharashtra, India.
1997: The Company purchases equity stakes in TDPL and MJ Pharma.
1997: The Company’s first international acquisition of Caraco Pharmaceutical Laboratories, USA.
1999: The Company acquires Milmet Labs and Gujrat Lyka Organics, India.
2000: The Company acquires Pradeep Drug Company, India.
2004: The Company acquires Phlox Pharma (India) and niche brands from Women’s First Healthcare (US).
2005: The Company completes buyout of manufatruing unit in Bryan, Ohio, US.
2005: The Company acquires ICN’s business in Hungary from Valent Pharma.
2005: The Company acquires intellectual property and assets of Able Labs from US District Bankruptcy court in New Jersey.
2008: The Company acquires Chattem Chemicals Inc, US.
2010: The Company acquires controlling stake in Israel-based Taro Pharmaceuticals, USA to effectively double company’s US businesses.
2012: The Company completes two more acquisitions in USA; Dusa Pharmaceuticals and the generic business of URL Pharmaceuticals.
2014: The Company acquires Ranbaxy in a $4 billion landmark transaction to create world’s fifth largest specialty generic pharma company.
2014: The Company acquires pharmalucence in USA.
2015: The Company acquires GSK’s Opiates business in Australia
2015: The Company acquires Insite Vision Inc. to strighthen branded ophthalmic portfolio in USA.
2016: Sun Pharma acquires 14 brands from Novartis in Japan
2016: Sun Pharma acquires Ocular Technologies, Sarl to strengthen branded ophthalmic portfolio
2016: Sun Pharma acquires branded oncology product Odomzo (sonidegib) from Novartis for global markets
2016: Sun Pharma acquires Biosintez to enhance presence in Russian market
Research & Manufacturing
1983:Sun Pharma sets up compact manufacturing facility for tablets and capsules at Vapi, Gujarat
1991: Sun Pharma establishes first research centre to create a base for strong product and process development
1991: Ranbaxy establishes state-of-the-art manufacturing facility for Cephalosporins at Mohali, Punjab, India
1995: Sun Pharma begins production at API manufacturing plant in Panoli, Gujarat, India.
1997: Sun Pharma establishes new research facility in Mumbai, India
1998: Sun Pharma begins operations at a new formulation unit in Silvassa, Gujarat, India
2001: Sun Pharma commences production at new formulations unit in Dadra, India
2004: Sun Pharma sets up new formulation unit in Jammu, India
2004: Sun Pharma commissions first joint venture manufacturing unit in Dhaka, Bangladesh
2015: Sun Pharma enters into research collaboration with Weizmann Institute of Science, Israel & Health Research Institute of Santiago, Spain for brain therapies
2016: International Centre for Genetic Engineering and Biotechnology (ICGEB) & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue
2017: Sun Pharma & National Institute of Virology (NIV), India sign agreement to fight Zika, Chikungunya and Dengue
Products & Innovations
1987: Sun Pharma begins sale of products across India
1988: Sun Pharma launches Monotrate and Angizem, first cardiology products that are sold till today
1989: Sun Pharma introduces gastroenterology products in India
1998: Sun Pharma acquires a basket of products from Natco Pharma
2014: Sun Pharma and Merck & Co. Inc. enter into licensing agreement for Tildrakizumab (MK-3222)
2016: Sun Pharma launches Imatinib Mesylate in USA
2016: Sun Pharma launches first branded ophthalmic product, BromSite in USA

Sun Pharmaceutical Company Ltd is a Mumbai, India based Multi-national pharmaceutical company. Established by Mr Dilip Shanghvi in 1983, the company had its first base in Vapi, Gujarat. Initially, it started with a two-person marketing team and launched five products, but now they have emerged as one of the largest pharma companies standing at a net income of 530 million USD. 


The Indian pharmastry has become the third-largest producer globally in terms of volumes and develops into a business of $36.7 billion from $20 billion in 2015. Sun Pharma is the second biggest and the most profitable pharmaceutical company in India, as well as the largest pharmaceutical company by market capitalisation on the Indian exchanges. Breaking grounds with Its records Sun pharma is indeed one trusted INDIAN MNC known for its various quality pharma products and is listed in multiple stock exchanges worldwide.

SERVICES

Sun Pharma is into the research area, sells pharmaceutical formulations and active pharmaceutical ingredients (APIs). With its horizons and products as vast as space, some of the well-known ailments Sun Pharma provides products for are

cardiology 
psychiatry 
neurology 
gastroenterology  
diabetology
 It also provides APIs such as warfarin, carbamazepine, etodolac, clorazepate, anti-cancers, steroids, peptides, sex hormones, and controlled substances.


MERGERS AND ACQUISITIONS
Sun Pharmaceuticals Ltd went through many mergers and acquisitions, but some of the game-changing were
 
In 1997, Sun took over Tamil Nadu's Dadha Pharmaceuticals Limited (TDPL), based in Chennai, nearly for their comprehensive gynaecology and oncology labels.
In 2008 Buys Chattem Chemicals, Inc., a manufacturer of controlled substances with an API facility.
On 6 April 2014, Sun Pharma declared that it would acquire 100% of Ranbaxy Laboratories Ltd., estimated at 4 billion USD. This turned tables for Sun, making them the largest pharmaceutical company in India, the largest Indian Pharma company in the US, and the 5th largest generic company globally.
In 2012 they acquired Dusa Pharmaceuticals, a dermatology based company.
Acquires majority stake in Taro Pharmaceutical Industries Limited, a multinational generic manufacturer with an established North American presence and a strong franchise in dermatology
In March 2015, Sun Pharma stated it had agreed to acquire GlaxoSmithKline's opiates company in Australia to grow its pain management collection.
In 2015 to strengthen its ophthalmic department, Sun Acquires InSite Vision Inc.'s portfolio in the USA.
 
MILESTONES
In 1996 sun pharma expanded its network to 24 countries.
In 1998 Sun Pharma launched its first cardiology products that are sold to date.
In 2007 Sun Pharma demerged its research unit known as SPARC becoming the first pure research company to get listed in the Indian stock exchange.
In 2013 Acquiring Ranbaxy made Sun Pharma, the 5th largest generic company in the world.
In 2016 they launched their first ophthalmic product in the USA known as BromSite.

ACHIEVEMENTS
In 2018 Sun Pharma bagged the best CSR Practices from The Economic Times (ET).
In 2017 Mr Dilip Shanghvi got the Entrepreneur of the Year Award by All India Management Association (AIMA).
In 2016 Dilip Shanghvi was honoured with Padma Shri Award by the Government of India.
In 2015 Sun Pharma got India Pharma Research & Development Award by the Ministry of Chemicals & Fertilizers, Government of India.
Sun Pharma got listed among the world's 100 Most Innovative Companies IN 2014, 2013 Asia's 50 fab companies, and both in 2012, FORBES.

ABOUT INVEST YADNYA

Invest Yadnya is an eLearning platform engaged in educating & simplifying the contents based on personal finance for all individuals. We have combined technology with financial planning expertise to assist an individual in meeting their financial objectives. We provide valuable time, money, as well as knowledge to create financial literacy in India.


We offer various products and services including, Personalized Financial Planning, Stock Market Analysis with eBook Subscriptions, Simplest Income Tax Information Bank, Comprehensive Mutual Fund Reviews, and Do-It-Yourself Financial Planning.

Invest Yadnya should be a choice because it offers unbiased and transparent stock analysis reports. Our work is knowledge-based and has specific proprietary methodologies and a stock research framework. We continuously keep updating our data and have the latest information available. 


We help our clients do extensive research on 950+ companies including, Sun Pharma stock fundamental analysis. You can find the latest Sun Pharma stock price on Invest Yadnya. We also provide our clients with the balance sheet of Sun Pharma. It helps the clients understand the financial position of the company before making any investment decisions. The Sun Pharma stock analysis helps the investors identify the intrinsic worth of the security. The Sun Pharma results provide a summary of how the business incurs revenues and expenses. We also offer our clients with the Sun pharma share price graph. 

A detailed stock article on Sun Pharma’s Performance Review is provided on our website, which offers an in-depth Sun pharma stock review. It gives an investor a sense of whether the company is growing, stable or deteriorating. This helps investors make a viable investment decision with a thorough discussion on Sun Pharma annual report & Sun Pharma research report.

Invest Yadnya offers numerous resources for Sun Pharma share analysis. With the available financials, price chart, ratios, etc., get a detailed Sun Pharma company analysis. With Invest Yadnya’s available resources, get an overview of the company, both from the qualitative and financial perspective. With this Sun Pharma fundamental analysis, the investors shall make a viable investment decision depending on your risk profile & other economic factors.

The Sun Pharma analysis gives the clients a better understanding of the company’s EPS, Debt-Equity Ratio etc. It helps clients take the first step in choosing which companies to invest in. 

The economic analysis of Sun Pharma overall helps allocate the equity in the Portfolio of an investor to add to its favourable returns.

To find the Sun Pharma ratio analysis & Sun Pharma stock chart, subscribe to our Equity Research and Stock Fundamental Analysis Tool, Stock-O-Meter.

Our website has information about 113 other Pharmaceuticals & Drugs companies that give insight into its financials. Companies include Divis Laboratories, Dr Reddys Laboratories, Cipla, Biocon, Aurobindo Pharma, Lupin, Torrent Pharmaceuticals, Cadila Healthcare, Abbott India, Glaxosmithkline Pharmaceuticals & many more.

Brands Of Sun Pharmaceutical Industries

Brands Of Sun Pharmaceutical Industries

undefined

Comment

Chat on WhatsApp
Caret UP Arrow
InvestYadnya Support
Typically replies in minutes
InvestYadnya Support
Hi there
Welcome to InvestYadnya.
We are available to assist you on WhatsApp.
Please click on the button below to chat with us.
(10 AM to 7 PM IST)
16:10
Chat with InvestYadnya